Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839366 | 1.00 | RORC (0.55) | RORCCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3449300 | 1.00 | RORC (0.55) | RORCCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1891481 | 0.94 | RORC (0.55) | RORCCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3025628 | 0.93 | RORC (0.54) | RORCCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5097178 | 0.93 | RORC (0.54) | RORCCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21892098 | 0.93 | RORC (0.54) | RORCCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2780389 | 0.93 | RORC (0.54) | RORCCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5097184 | 0.93 | RORC (0.54) | RORCCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2782549 | 0.92 | SLC18A2 (0.53) | RORCCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6594128 | 0.92 | RORC (0.53) | RORCCHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318759-B2 | Pyrrolidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8012998-B2 | Pyrrolidine aryl-ether as NK-3 receptor antagonists | Hoffmann—La Roche Inc. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7812021-B2 | Pyrrolidine aryl-ether as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20090054644-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | RORC 1018/4885CHRM2 367/4885CHRM4 359/4885 |
| US-20090054644-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRD1, OPRK1 | RORC 456/4885CHRM2 342/4885CHRM4 232/4885 |
| US-20090042896-A1 | PYRROLIDINE ARYL-ETHER AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | RORC 517/4885CHRM2 306/4885CHRM4 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.